Insights into New Treatments for Early Psychosis from Genetic, Neurodevelopment, and Cognitive Neuroscience Research
Insights into New Treatments for Early Psychosis from Genetic, Neurodevelopment, and Cognitive Neuroscience Research
Genetic and epidemiological studies have begun to identify specific “vulnerability” genes and environmental risk factors that, together, may contribute to neurodevelopmental abnormalities and the emergence of psychosis. Neuroimaging and electrophysiological studies also demonstrate altered developmental trajectories and evidence of compensatory changes, which perhaps reflects a period of neurotoxicity coinciding with emerging psychosis. These occur at a time of increased brain plasticity. There is therefore an opportunity to provide interventions that may disrupt the neuropathological processes and remediate cognitive and functional deficits to alter the progressive trajectory of the illness. Adequately powered clinical trials that utilize information gained from biomarker studies are now needed to determine the most effective individualized interventions. A synergistic treatment approach that offers precision pharmacologic intervention combined with remediation techniques is likely to have the greatest impact during the early course of illness. Published in the Strungmann Forum Reports Series.
Keywords: Biomarker, Early psychosis, Genes, Neuroimaging, Electrophysiology, Cognitive remediation, Precision pharmacology, Schizophrenia
MIT Press Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.
Please, subscribe or login to access full text content.
If you think you should have access to this title, please contact your librarian.
To troubleshoot, please check our FAQs, and if you can't find the answer there, please contact us.
